ABOUT RISEN
Risen Group
Corporate Culture
Development History
R&D Manangement Team
Partners
R&D
PIPELINE
NEWS
Company news
IP granted
Publications
CONTACT US
繁体
简体
RISEN PHARMA
ABOUT RISEN
Risen Group
Corporate Culture
Development History
Management Team
Partners
R&D
PIPELINE
NEWS
Company news
IP granted
Publications
CONTACT US
Company news
IP granted
Publications
2026-07-20
Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
Details
Year:
All
2026
2025
2024
2023
2022
2021
2020
2024-11-13
Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.
Detail
2024-03-07
Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!
Detail
2023-12-20
Risen found status in the "2023 Hurun Global Cheetah Enterprise List"
Detail
2023-06-13
Congratulations! Risen successfully acquired Biosafety Laboratory level 2 (BSL-2) qualification.
Detail
2023-04-10
Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”
Detail
2023-03-13
Congratulations! Risen was entitled as a "special and innovative" small to medium-sized enterprise in Shanghai
Detail
上一页
1
2
3
下一页
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Jiangsu Xuzhou R&D Center
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved
沪ICP备16020731号-1
Design by:
yushangweb